Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) to Post FY2027 Earnings of $0.18 Per Share, HC Wainwright Forecasts

Mind Medicine (MindMed) Inc. (NASDAQ:MNMDGet Rating) – Investment analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Mind Medicine (MindMed) in a report released on Thursday, January 19th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $0.18 per share for the year. HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($2.33) per share.

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.02.

Other equities research analysts have also issued reports about the company. Roth Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Mind Medicine (MindMed) in a research note on Friday, December 9th. Maxim Group lowered their price objective on Mind Medicine (MindMed) from $22.50 to $8.00 in a research note on Monday, November 14th. UBS Group initiated coverage on Mind Medicine (MindMed) in a research note on Thursday, December 15th. They issued a “buy” rating and a $21.00 price objective on the stock. Royal Bank of Canada initiated coverage on Mind Medicine (MindMed) in a research note on Wednesday, November 16th. They issued an “outperform” rating on the stock. Finally, Canaccord Genuity Group lowered their price objective on Mind Medicine (MindMed) from $22.00 to $18.00 in a research note on Monday, November 21st. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Mind Medicine (MindMed) presently has a consensus rating of “Buy” and an average target price of $33.13.

Mind Medicine (MindMed) Stock Up 7.3 %

Shares of MNMD opened at $3.54 on Friday. Mind Medicine has a 12-month low of $2.12 and a 12-month high of $22.20. The firm has a market capitalization of $133.00 million, a price-to-earnings ratio of -1.50 and a beta of 1.63. The stock’s 50-day moving average price is $2.74 and its 200 day moving average price is $5.84.

Institutional Investors Weigh In On Mind Medicine (MindMed)

A number of large investors have recently bought and sold shares of the business. Exchange Traded Concepts LLC grew its position in Mind Medicine (MindMed) by 235.1% during the 4th quarter. Exchange Traded Concepts LLC now owns 14,955 shares of the company’s stock worth $33,000 after acquiring an additional 10,492 shares during the last quarter. Telemetry Investments L.L.C. acquired a new position in Mind Medicine (MindMed) during the 3rd quarter worth $369,000. Empery Asset Management LP acquired a new position in Mind Medicine (MindMed) during the 3rd quarter worth $656,000. LMR Partners LLP acquired a new position in Mind Medicine (MindMed) during the 3rd quarter worth $36,000. Finally, Virtu Financial LLC acquired a new position in Mind Medicine (MindMed) during the 3rd quarter worth $126,000. 20.44% of the stock is currently owned by institutional investors.

About Mind Medicine (MindMed)

(Get Rating)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Featured Articles

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.